Creating a free account will enable you to subscribe to our daily and weekly email newsletters, as well as customize your reading experience to show only the categories most relevant to you.
Signing up only take a few minutes, so why not give it a try and see what you've been missing out on.
The evolution of hyperswarming, pathogenic bacteria might sound like the plot of a horror film, but such bugs really have repeatedly evolved in a lab, and the good news is that they should be less of a problem to us than their less mobile kin. That's because those hyperswarmers, adorned with multiple whipping flagella, are also much worse at sticking together on surfaces in hard-to-treat biofilms. They might even help us figure out a way to develop anti-biofilm therapies for use in people with cystic fibrosis or other conditions, say researchers who report their findings in Cell Reports, a Cell Press publication.
The findings are also a textbook example of real-time experimental evolution. What's more, says Joao Xavier of Memorial Sloan Kettering Cancer Center, they are a "unique example of strikingly parallel molecular evolution."
In other words, the evolution that he and his team witnessed was repeatable, all the way down to the molecular level.
The researchers didn't set out with the goal to evolve hyperswarmers, but they did passage Pseudomonas aeruginosa on special plates over a period of days. On those plates, bacteria that could spread out had an advantage in harvesting nutrients from the surface, and within a matter of days, some of those bacteria started hyperswarming.
Investigation of the bacteria showed that P. aeruginosa gained its hyperswarming ability through a single point mutation in a flagellar synthesis regulator (FleN). As a result, the bacteria, which usually have one single flagellum, were locked into a multi-flagellated state. They became better at moving around to cover a surface, but much worse at forming densely packed, surface-attached biofilm communities. All told, the researchers saw this new ability independently arise 20 times.
"The fact that the molecular adaptations were the same in independent lineages suggests evolution may be, to some extent, predictable," says Xavier.
The findings may be very important because biofilms are a major problem in clinical settings. Infectious biofilms are hard to remove and difficult to kill with antibiotics. Drugs that target FleN or that otherwise make bacteria better at spreading out and worse at settling down could leave them more vulnerable to antibiotics and easier to get rid of.
Cell Reports, van Ditmarsch et al.: "Convergent Evolution of Hyperswarming Leads to Impaired Biofilm Formation in Pathogenic Bacteria." 10.1016/j.celrep.2013.07.026
Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our Infectious Diseases / Bacteria / Viruses category page for the latest news on this subject.
Please use one of the following formats to cite this article in your essay, paper or report:
Press, Cell. "Drugs that target FleN could lead to anti-biofilm therapies." Medical News Today. MediLexicon, Intl., 19 Aug. 2013. Web.
8 Dec. 2013. <http://www.medicalnewstoday.com/releases/264916>
Press, C. (2013, August 19). "Drugs that target FleN could lead to anti-biofilm therapies." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
If you write about specific medications, operations, or procedures please do not name healthcare professionals by name.
For any corrections of factual information, or to contact the our editorial team, please use our feedback form. Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
This page was printed from: http://www.medicalnewstoday.com/releases/264916.php
Visit www.medicalnewstoday.com for medical news and health news headlines posted throughout the day, every day.
© 2004-2013 All rights reserved. MNT (logo) is the registered trade mark of MediLexicon International Limited.